CN116218791B - 一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用 - Google Patents
一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用 Download PDFInfo
- Publication number
- CN116218791B CN116218791B CN202211083453.6A CN202211083453A CN116218791B CN 116218791 B CN116218791 B CN 116218791B CN 202211083453 A CN202211083453 A CN 202211083453A CN 116218791 B CN116218791 B CN 116218791B
- Authority
- CN
- China
- Prior art keywords
- virus
- generation
- titer
- cells
- rabies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 122
- 229960003127 rabies vaccine Drugs 0.000 title claims abstract description 25
- 238000000338 in vitro Methods 0.000 title claims abstract description 21
- 238000001727 in vivo Methods 0.000 title claims abstract description 11
- 238000012136 culture method Methods 0.000 title claims description 12
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000012258 culturing Methods 0.000 claims abstract description 12
- 238000012216 screening Methods 0.000 claims abstract description 11
- 238000003860 storage Methods 0.000 claims abstract description 6
- 238000012750 in vivo screening Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 34
- 241000711798 Rabies lyssavirus Species 0.000 claims description 24
- 241000699670 Mus sp. Species 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 15
- 238000004113 cell culture Methods 0.000 claims description 10
- 239000012888 bovine serum Substances 0.000 claims description 9
- 239000002356 single layer Substances 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000287 crude extract Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 238000012449 Kunming mouse Methods 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- 230000000120 cytopathologic effect Effects 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000035772 mutation Effects 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 10
- 206010037742 Rabies Diseases 0.000 description 7
- 210000001840 diploid cell Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000711931 Rhabdoviridae Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20151—Methods of production or purification of viral material
- C12N2760/20152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供基于体内外交叉的狂犬病疫苗病毒的培养方法,包括体内筛选、体外筛选两个过程,重复2次,即仅需传4代,滴度明显提高,从实施例数据可以看出PM病毒滴度从2.5 logLD50/mL升至7.3 logLD50/mL以上,PV病毒滴度从2.0 logLD50/mL升至7.5 logLD50/mL以上,传代次数少、耗时短,成本低,毒种滴度明显提高;2)病毒滴度稳定性好,可以满足长期存放的需求;3)本发明制备的毒种PM株传代稳定性也进行了相应的验证,结果显示,对比E0代病毒毒种的基因序列(如SEQ ID NO 1所示),第11代毒种进行全基因序列(如SEQ ID NO 2所示)未发现有任何突变。
Description
技术领域
本发明涉及一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用,属于疫苗预防狂犬病技术领域。
背景技术
狂犬病(rabies)是由狂犬病病毒(rabies virus,RABV)引起的人兽共患病,据WHO统计,全球150多个国家和地区存在狂犬病,全球每年因狂犬病致死人数高达6万人。其中95%发生于亚洲和非洲,中国是狂犬病发病第二大国,仅次于印度。RABV专门侵染神经系统,人感染后一旦出现神经症状,致死率几乎100%,目前尚无有效治疗药物。目前国内兽用疫苗推广难度大,疫苗覆盖率低,传染源难控制,因此对于人用狂犬疫苗的需求居高不下。
狂犬病毒属于弹状病毒科(Rhabdoviridae)狂犬病毒属(Lyssavirus),是一种由大约12000个核苷酸组成的包膜型负链RNA病毒。病毒呈子弹状,长130-250nm,直径60-100nm,核衣壳呈螺旋对称,表面具有包膜,内含有单链RNA。病毒包膜包含糖基化的G蛋白,G蛋白上的树突可以结合在细胞上。基质(M)蛋白位于内病毒包膜内部,靠近里面的病毒核蛋白(N)紧紧地将病毒RNA结合在一起形成核衣壳核。这个核心和一个大的转录酶L蛋白以及磷酸化的P蛋白,是狂犬病毒核衣壳(RNP)。
目前市场上的人用狂犬病疫苗品种主要有四种:鸡胚、鸭胚疫苗,地鼠肾细胞原代培养疫苗,Vero细胞疫苗,人二倍体疫苗。其中,前两种疫苗产量限制,且有可能存在外源毒性因子的问题;第三种疫苗不能保证细胞基质本身存在的安全性和致瘤性问题,且需要严格控制其DNA残留量;第四种不含外源污染因子和致瘤性,且残留DNA无危险性,是WHO公认的金标准疫苗。以细胞为基质生产的狂犬病疫苗的制备过程主要是细胞培养、病毒增殖,然后收获病毒液、灭活、浓缩、纯化处理制备出半成品,最后制剂、冻干即得成品。
云南沃森在在中国专利公开号CN103468649A中公开了一种人用狂犬疫苗毒种在人二倍体细胞上的快速适应方法,将新鲜狂犬病毒接种人二倍体细胞上,带毒传代,传代12~15代,病毒滴度从第P1代的3.0 logLD50/mL升至P15代的7.0 logLD50/mL以上。北京天坛生物在中国专利公开号CN103397000A的专利中提供了一种狂犬病病毒人二倍体细胞适应株及其制备方法,是指一种狂犬病病毒aG株人二倍体细胞(2BS)适应株。浙江普康在中国专利公开号CN102093983A中是将狂犬病固定毒CTN-1V5株连续在人二倍体细胞(KMB17)中传代,并以终末稀释法筛选出滴度较高的病毒,从而获得适应于KMB17细胞并具有良好免疫原性和传代稳定性的狂犬病毒株,培育出可在KMB17细胞高效增殖的狂犬病疫苗毒种(CTN-DK株)。
但上述狂犬病疫苗存在如下几个问题:1)狂犬疫苗供不应求,尤其是人二倍体狂犬病疫苗,由于其不含外源污染因子、细胞无致瘤性、残留DNA无危险,故更具安全性,但其传代周期较长,达12-15代,病毒滴度才达至7.0 logLD50/mL;2)狂犬病疫苗为灭活苗,其抗原回收率低,故需要前期毒种的滴度较高;3)毒种在-80℃下保存,冻融后滴度会有所下降。
发明内容
本发明为了解决现有技术中存在的上述缺陷和不足,提供了一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用。
为解决上述技术问题,本发明提供一种基于体内外交叉的狂犬病疫苗病毒的培养方法,包括以下步骤:
S1体内筛选:将E0代狂犬病毒毒种在流水中融化、倍比稀释后,小鼠脑内接种,取发病小鼠鼠脑分离出病毒,对分离出的病毒进行滴度检测,符合滴度要求的记为E1代病毒;
S2体外筛选:
将体外筛选所用的细胞复苏后,在细胞瓶中进行消化、传代,35~37℃培养箱静置培养3-7天,至长成致密单层;
将E1代病毒离心处理后取上清按照MOI 0.001-0.1接种于细胞瓶中的单层细胞,补加细胞培养液至覆盖细胞表面,35~37℃培养箱中孵育1-2h;同时,取离心处理后的E1代病毒按照MOI 0.001-0.1接种于长满单层细胞的96孔板中用于细胞病变检测;
培养瓶中继续补加培养液至培养瓶体积的5-8%,培养3-5天;检测感染病毒细胞的比例,病毒感染比例低于80%的培养瓶淘汰;对于高于80%的培养瓶,弃去培养液,按照1:1进行再次传代,35~37℃培养箱静置培养2-3天,弃去细胞培养液后,加入1.5-2倍的病毒培养液,置于33~35℃培养箱中培养3-7天,间隔时间段检测病毒感染细胞的比例,对于感染时间最短、感染比例最高的细胞取上清液,置于-70度以下保存,记为E2代病毒;
S3将E2代病毒重复步骤S1获得E3代病毒,将E3代病毒重复步骤S2获得细胞上清液为E4代病毒;
S4保存E4代病毒,并将步骤S3的细胞消化成细胞悬液,1:1传代培养2-3天,取上清病毒液;
S5病毒提取:将E4代病毒和步骤S4传代培养后的上清病毒液合并,在2-8度条件下,与预冷的PEG溶液以2:1的比例混合、过夜,离心后收集病毒沉淀,加入0.01M PBS过夜溶解,离心得到病毒粗提液;将病毒粗提液于50~100KD的超滤浓缩管中浓缩,后过0.22μm过滤膜过滤,获得浓缩毒种;
S6向浓缩毒种中加入15-30%的牛血清,分装保存、备用。
进一步,用于体外筛选的细胞为Vero细胞、WI-38、MRC-5、2BS或KMB-17。
进一步,细胞培养液为含2~10%牛血清和0.01~0.1%谷氨酰胺的MEM培养液,pH为6.8~7.2;病毒培养液为含1~5%牛血清、0.2~2%人血白蛋白和0.01%~0.1%谷氨酰胺的MEM培养液,pH为7.5~8.0;PEG溶液的浓度为15~30%。
进一步,步骤S1中,小鼠为11-13g的KM小鼠,每每只注射毒种0.03mL,每个稀释度接种4-6只小鼠。
进一步,步骤S1中,小鼠脑内接种后,若3-4天发现小鼠死亡,则进行无菌取鼠脑进行病毒的滴度检测;若接种15天仍不发病或接种后3日内死亡的小鼠均淘汰。
进一步,E1代病毒的滴度不低于4.0 lg CCID50/mL。
进一步,狂犬病病毒毒种为PM株或PV株。
本发明还提供一种狂犬病疫苗的制备方法,将上述培养方法获得的浓缩毒种,制备成狂犬病疫苗。
本发明所达到的有益技术效果:
1)本发明提供的方法,方法简单易操作,仅传4代,传代次数少、耗时短,成本低,从实施例数据可以看出PM病毒滴度从2.5 logLD50/mL升至7.3 logLD50/mL以上,PV病毒滴度从2.0 logLD50/mL升至7.5 logLD50/mL以上,毒种滴度明显提高;2)对本发明制备的毒种进行长达2年的长期稳定性验证检测,结果表明,滴度仍然可以达到7.0 logLD50/mL以上,下降程度小,毒种滴度稳定,能满足生产长期储存需求;3)本发明制备的毒种PM株传代稳定性也进行了相应的验证,结果显示,对比E0代病毒毒种的基因序列(如SEQ ID NO 1所示),第11代毒种进行全基因序列(如SEQ ID NO 2所示)未发现有任何突变。
SEQ ID NO 1如下所示:
ATGGATGCCGACAAGATTGTGTTCAAAGTCAATAATCAGGTGGTCTCTTTGAAGCCTGAGATTATCGTGGATCAATATGAGTACAAGTACCCTGCCATCAAGGATTTGAAAAAGCCTTGTATCACCCTAGGGAAAGCCCCCGACTTGAACAAAGCATACAAATCAGTTTTATCAGGCATGAATGCCGCCAAACTTGATCCGGATGATGTATGCTCCTACTTGGCAGCAGCAATGCAGTTCTTTGAGGGGACATGTCCGGAAGACTGGACCAGCTATGGAATCCTGATTGCACGAAAAGGAGACAGGATCACCCCAAACTCTCTAGTGGAGATAAAGCGTACTGATGTAGAAGGGAATTGGGCTCTGACAGGAGGCATGGAATTGACAAGGGACCCCACTGTCTCTGAACATGCATCTTTAGTCGGTCTTCTCCTGAGTCTGTACAGGTTGAGCAAAATATCAGGACAGAACACTGGTAACTATAAGACAAACATTGCAGATAGGATAGAGCAGATTTTCGAGACAGCACCTTTTGTTAAGATCGTGGAACACCATACCCTAATGACAACTCACAAGATGTGTGCTAATTGGAGTACTATACCGAACTTCAGATTTTTGGCCGGAACCTACGACATGTTTTTCTCACGGATTGAGCATCTGTATTCGGCAATCAGAGTGGGCACAGTCGTCACCGCTTATGAAGACTGCTCAGGACTGGTATCGTTTACAGGGTTCATAAAGCAGATCAATCTCACCGCAAGGGAAGCAATACTATATTTCTTCCACAAGAACTTTGAGGAAGAGATAAGAAGAATGTTCGAGCCAGGGCAAGAGACAGCTGTTCCTCACTCTTATTTCATCCACTTCCGTTCACTAGGCTTGAGTGGGAAGTCTCCTTATTCATCGAATGCTGTCGGTCATGTGTTCAATCTCATTCACTTTGTTGGATGCTACATGGGTCAAGTCAGATCTCTAAATGCGACGGTTATTGCTGCATGTGCCCCTCATGAGATGTCTGTTCTAGGGGGCTATTTGGGAGAGGAATTCTTCGGAAAAGGGACATTTGAAAGAAGGTTCTTCAGAGACGAGAAAGAACTTCAAGAATATGAGGCGGCTGAACTAACAAAGACCGACGTGGCACTGGCAGATGACGGAACCGTCAACTCTGATGACGAGGACTATTTCTCCGGTGAAACCAGAAGTCCAGAAGCTGTCTATACTCGAATCATGATGAATGGAGGTCGACTGAAGAGATCTCATATACGGAGATATGTCTCAGTCAGTTCCAATCATCAAGCCCGTCCAAACTCATTCGCCGAATTTTTAAACAAGACGTATTCGAATGACTCATAAGGAGTTGATTGACAGGGTGCCGGAAATCTATAGATTGTATATATCCATCATGAAAAAAACTAACACTCCTCCTTTCAAACCATCCCAAATATGAGCAAGATCTTTGTTAATCCGAGTGCAATCAGAGCCGGTCTGGCCGATCTTGAGATGGCCGAAGAGACTGTTGATCTGATCAACAGAAACATAGAAGACAATCAGGCTCATCTCCAGGGAGAACCCATAGAAGTGGACAACCTCCCTGAGGACATGAAGCGACTTCACCTGGACGATGAAAAATCGTCCAACCTTGGTGAGATGGTTAGGGTGGGAGAAGGCAAGTATCGAGAGGACTTTCAGATGGATGAGGGAGAGGACCCCAACCTCCTGTTCCAATCGTACCTGGATAATGTCGGAGTCCAAATAGTCAGACAAATGAGGTCAGGAGAGAGATTCCTCAAGATATGGTCACAGACCATAGAGGAAATTGTATCCTATGTCACGGTCAACTTTCCTAACCCTCCAAGAAGGTCTTCGGAGGATAAATCAACCCAGACTACTGGCCGAGAGCTCAAGAAGGAGACAACGTCTGCTTTCTCTCAGAGAGAAAGCCAACCTTCGAAAGCTAGGATGGTGGCTCAAGTTGCCTCTGGTCCTCCAGCCCTTGAATGGTCAGCCGCCAATGAAGAAGATGATCTATCAGTAGAGGCTGAGATCGCTCATCAGATTGCTGAAAGCTTTTCCAAGAAGTACAAGTTTCCCTCCCGATCTTCAGGAATATTCTTGTATAATTTTGAGCAACTGAAGATGaACCTTGACGACATAGTTAAAGAGGCAAAAAATGTACCGGGCGTGACCCGTCTGGCCCATGATGGATCCAAAATCCCCCTGAGATGTGTACTGGGATGGGTCGCTTTGGCCAATTCCAAAAAATTCCAATTACTAGTCGAGGCTGACAAGCTAAGCAAAATCATGCAAGATGATTTGAATCGCTATACATCCTGCTAACCGAGTTTTCGAACTCAGTCCCTCCAGATAATGAAAACTGAGATGTTATGGAGTAGACATGAAAAAAACAGGCAACACCACTGATAAAATGAACGTTCTACGCAAGATAGTGAAAAAATGTAGGGATGAGGACACTCAAAAGCCCTCTCCTGTGTCAGCCCCTCCGGATGACGATGACCTGTGGCTTCCACCTCCTGAATATGTCCCGCTGAAAGAACTCACAAGCAAGAAGAACATGAGGAACTTTTGTGTCAACGGGGATGTTAAAGCGTGTAGCCCAAATGGTTACTCATTCAGGATTTTGCGGCACATTCTGAGATCATTCAACGAGATATACTCTGGGAATCATAGGATGATTGGGTTAGTCAAAGTTGTTGTTGGACTAGCTTTATCAGGAGCTCCAGTACCTGAGGGCATGAACTGGGTATACAAATTGAGGAGAACCCTTATATTCCAGTGGGCTGATTCCAGGGGCCCTCTTGAAGGGGAGGAGTTAGAATACTCTCAAGAGATCACTTGGGATGATGATACTGAATTCGTCGGATTGCAAATAAGAGTGAGCGCAAGACAATGTCATATTCAAGGCAGGATCTGGTGTATCAACACGAACTCGAGGGCATGTCAACTATGGTCTGACATGTCTCTTCAGACACAAAGGTCTGAAGAGGACAAAGACTCTTCTCTGCTTCTAGAATAATCAGATTATATCCTGCAAGTTTATCACTTGTTTACCTCTGGAGGAGAGAGCATACAGGCTTGACTCCGATCCTTGGGAGCAATAGAACAAAAAAACACACGTTATGGTGCCGTTAAATCGCTGCATTTTATCAAAGTCAAGTTGATAACCTTTACATTTTGAGCCTCTTGGATGTGAAAAAAACTATTAACATCCCTCAAAAGACTTAAGGAAAGATGGTTCCTCAGGTTCTTTTGTTTGTACCCCTTCTGGGTTTTTCGTTGTGTTTCGGGAAGTTCCCCATTTACACGATACCAGACGAACTTGGTCCCTGGAGCCCTATTGACATACACCATCTCAGCTGTCCAAATAACCTGGTTGTGGAGGATGAAGGATGTACCAACCTGTCCGAGTTCTCCTACATGGAACTCAAAGTGGGATACATCTTAGCCATCAAAGTGAACGGGTTCACTTGCACAGGTGTTGTGACAGAGGCAGAGACCTACACCAACTTTGTTGGTTATGTCACAACCACATTCAAGAGAAAGCATTTCCGCCCCACCCCAGACGCATGTAGAGCCGCGTATAACTGGAAGATGGCCGGTGACCCCAGATATGAAGAGTCCCTACACAATCCATACCCCGACTACCACTGGCTTCGAACTGTAAGAACCACCAAAGAGTCCCTCATTATCATATCCCCAAGTGTGACAGATTTGGACCCATATGACAAATCCCTTCACTCAAGGGTCTTCCCTGGCGGAAAGTGCTCAGGAATAACGGTGTCCTCTACCTACTGCTCAACTAACCATGATTACACCATTTGGATGCCCGAGAATCCGAGACCAAGCACACCTTGTGACATTTTTACCAATAGCAGAGGGAAGAGAGCATCCAAAGGGAACAAGACTTGCGGCTTTGTGGATGAAAGAGGCCTGTATAAGTCTCTAAAAGGAGCATGCAGGCTCAAGTTATGTGGAGTTCTTGGACTTAGACTTATGGATGGAACATGGGTCGCGATGCAAACATCAGATGAGACCAAATGGTGCCCTCCAGATCAGTTGGTGAATTTGCACGACTTTCGCTCAGACGAGATTGAGCATCTCGTTGTGGAGGAGTTAGTCAAGAAAAGAGAGGAATGTCTGGATGCATTAGAGTCCATCATGACCACCAAGTCAGTAAGTTTCAGACGTCTCAGTCACCTGAGaAAACTTGTCCCAGGGTTTGGAAAAGCATATACCATATTCAACAAAACCTTGATGGAGGCTGATGCTCACTACAAGTCAGTCCGGACCTGGAATGAGATCATCCCCTCAAAAGGGTGTTTGAAAGTTGGAGGAAGGTGCCATCCTCATGTGAACGGGGTGTTTTTCAATGGTATAATATTAGGGCCTGACGGCCATGTCCTAATCCCAGAGATGCAATCATCCCTCCTCCAGCAACATATGGAGTTGTTGAAATCTTCAGTTATCCCCCTGATGCACCCCCTGGCAGACCCTTCTACAGTTTTCAAAGAAGGTGATGAGGCTGAGGATTTTGTTGAAGTTCACCTCCCCGATGTGTACAAACAGATCTCAGGGGTTGACCTGGGTCTCCCGAACTGGGGAAAGTATGTATTGATGACTGCAGGGGCCATGATTGGCCTGGTGTTGATATTTTCCCTAATGACATGGTGCAGAAGAGCCAATCGACCAGAATCGAAACAACGCAGTTTTGGAGGGACAGGGAGGAATGTGTCAGTCACTTCCCAAAGCGGAAAAGTCATACCTTCATGGGAATCATATAGGAGTGGAGGTGAGATCAGACTGTGAAGGCCGGTCATCCTTTTGACGATTCCAGTCCCGAGGATAACCTCCTCTCGGGATTGGGGGGAATCTTTGGATCCAGTAGTCCTCCTTGAACTCCGTCCAACAGAGTAGATTCAAGAGTCATAAGACTTTCATTAATCATTTCAGTTGATCAGACATGGTCGTGTAGATTCTCTTAATACGGGAGATCTTCTAGCAGTTTCAGTGACCAACGGTGCTTTCATTCTCCAGGAACTGATACCAAAGGTTGTGGACAGGCCAAGGGGTACTTCGGATGACTCTGTGCTTGGGCACAGAAAGAGGTCGTAGTGTGCCCCCCGATAGCGGACTCGACATGAATCAACTAAGAAAGGCAATCTGCCTCCCATGATGGACATAAGCAATAGTTCACAACCATCTTGCATCTCAGTGAAGTGTACATAACTATTGAGGGCTGGGTCATCTAAGCATTTCAGTCGAGAAAAAAACTGTAGACCAAAAGAACAACTAGCAACACTTCTCATCCAGAGACCCATATCAAGATGCTAGATCCGGGAGAGGTTTATGATGACCCTGTTGATCCAATTGAGTCAGAGGCTGAACCCAGAGGAACCCCCACTGTCCCCAACATCTTGAGGAACTCCGACTACAATCTCAATTCTCCTTTGATAGAGGATCCTGCCAAACTAATGTTAGAATGGTTGAATACAGGGAACAGACCTTATCGGATGGCCTTGACAGACAATTGCTCCAGGTCTTACAAAGTTTTGAAAGATTATTTCAAGAAAGTAGATTTGGGTTCTCTCAAAGTGGGCGGAACTGCTGCACAGTCAATGGTTTCTCTCTGGTTGTGTGGTGCCCACTCTGAATCAAACAGGAGCCGGAGATGTATAACCGACTTGGCCCATTTCTATTCCAAGTCATCCCCCATAGAGAAGCTATTGAATTGTACGTTAGGAAACAGAGGCCTGAGAATCCCACCAGAGGGGGTGTTAAATTGCCTCGAGAGGGTCAATTATGACAAGGCATTTGGGAGGTATCTGGCCAACACGTATTCCTCTTACTTGTTTTTCCATGTAATCACCTTATACATGAATGCCTTAGACTGGGAAGAGGAAAAGACCATCCTGGCATTATGGAAAGATATAACCTCAGTGGATACCGAGAAGGACTTGGTCAAATTCAAAGATCAAATATGGGGACTGTTGATTGTGACAAAGGACTTTGTTTACTCTCAGAGTTCAAACTGTCTTTTTGACAGAAACTACACACTGATGCTAAAGGATCTTTTCTTGTCTCGATTCAACTCCTTAATGATTCTGCTTTCTCCCCCTGAGCCCCGATACTCAGATGACTTAATATCTCAGCTGTGCCAGCTATACATCGCTGGGGATCAAGTCTTGTCCATGTGTGGGAACTCCGGCTATGaAGTCATCAAAATATTGGAGCCATATGTCGTGAACAGTTTGGTCCAGAGGGCAGAGAAGTTTAGGCCTCTCATCCACCCCTTGGGAGACTTTCCTATGTtCATAAAAGACAAGGTGAATCAACTTGAAGGGACTTTTGGTCCCAGTGCAAAGAGGTTTTTTAGGGTTTTAGATCAATTCGACAACATACATGACTTAGTATTTGTGTATGGCTGTTACAGACATTGGGGGCACCCCTATATAGATTATCGGAAGGGTCTGTCGAAACTATATGATCAAGTTCACATTAAGAAAGTAATAGATAAGTCCTACCAGGAGTGTTTAGCAAGTGACTTGGCCAGAAGGATCCTCAGATGGGGATTTGACAAGTACTCCAAATGGTATCTAGATTCAAGATTCCTTGCCCGAGACCACCCCTTGACTCCTTATGTCAAGACCCAAACATGGCCACCCAAACATATAGTAGACTTGGTGGGGGACACATGGCATAAGCTCCCGATCACGCAGATCTTTGAGATTCCTGAATCAATGGACCCGTCAGAGATACTGGATGACAAATCACATTCTTTCACCAGAACAAGGTTAGCTTCTTGGCTGTCAGAGAACCGAGGGGGGCCTGTTCCTAGCGAGAAGGTCATTATCACGGCCCTGTCTAAGCCACCTGTCAATCCCCGAGAGTTTTTGAAATCTATAGACCTCGGAGGATTGCCAGATGAGGATTTGATAATTGGCCTCAAACCAAAGGAACGGGAGTTGAAGATCGAGGGCCGATTCTTTGCTCTAATGTCATGGAATCTAAGATTATATTTTGTCATCACCGAAAAGCTCTTGGCCAACTACATTTTGCCACTTTTTGACGCACTGACTATGACAGACAACCTGAACAAGGTGTTCAAAAAGTTGATCGACAGGGTCACCGGGCAAGGGCTTTTGGACTATTCTAGGGTCACATACGCATTTCACCTGGACTATGAGAAATGGAACAATCATCAAAGATTGGAGTCAACAGAGGATGTATTTTCTGTCCTAGATCAGGTGTTTGGATTGAAGAGGGTGTTTTCTAGAACACACGAGTTTTTTCAGAAGTCCTGGATCTATTATtCAGACAGATCAGACCTCATTGGGTTATGGGAGGACCAAATATATTGCTTGGATATGTCTAACGGCCCAACTTGCTGGAATGGCCAAGATGGCGGGCTAGAGGGCTTACGGCAGAAGGGCTGGAGTCTAGTCAGTTTATTAATGATAGATAGAGAATCTCAAACCAGGAACACAAGAACCAAGATACTAGCTCAAGGAGACAACCAGGTTCTGTGTCCTACATACATGTTGTCACCGGGATTGTCTCAAGAGGGGCTTCTCTATGAGTTAGAGAGCATATCAAGGAATGCACTCTCAATATACCGAGCTATCGAGGAAGGAGCATCTAAGCTGGGGTTGATCATCAAGAAGGAAGAGACCATGTGTAGTTATGACTTTCTCATATATGGGAAGACCCCCTTATTTCGAGGCAACATATTGGTGCCTGAATCCAAAAGATGGGCCCGAGTCTCTTGCATCTCTAACGACCAAATAGTCAACCTCGCCAATATAATGTCGACAGTATCCACCAATGCGCTGACAGTGGCACAACACTCTCAATCTCTGATCAAACCTATGAGGGATTTTCTGCTCATGTCAGTACAGGCAGTTTTCCACTACCTGTTGTTTAGCCCAATCCTAAAAGGCAGAGTTTATAAGATTCTGAGTGCTGAAGGGGAGAGCTTTCTCCTAGCCATGTCGCGGATAATCTACCTAGATCCTTCTTTGGGAGGGGTGTCTGGAATGTCTCTCGGGAGGTTCCATATACGTCAGTTCTCAGACCCTGTCTCTGAAGGGTTGTCATTCTGGAGAGAGATCTGGTTAGGCTCTCACGAGTCCTGGATTCACGCGTTGTGTCAAGAGGCCGGGAACCCCGATCTTGGAGAGAGAACACTCGAGAGCTTCACTCGCCTTTTAGAAGATCCTACTACCTTAAATATCAAAGGAGGGGCCAGCCCTACCATTCTACTCAAGGATGCTATCAGAAAGGCTCTGTACGACGAGGTGGACAAGGTGGAAAATTCAGAGTTTCGAGAGGCAATCCTGCTGTCCAAGACCCATAGAGATAACTTTATACTCTTTTTAAAATCTGTTGAGCCTCTGTTCCCTCGATTTCTCAGTGAGCTCTTCAGTTCGTCTTTCTTGGGAATACCGGAGTCAATCATTGGACTGATACAAAACTCCCGGACAATAAGAAGGCAGTTTAGAAAGAGTCTCTCAAGAACTTTAGAAGAGTCCTTCTACAACTCAGAGATCCACGGGATTAATCGGATAACCCAGACACCTCAAAGGGTCGGAAGGGTGTGGCCTTGCTCTTCAGAGAGGGCAGATCTACTTAGGGAGATCTCTTGGGGGAGGAAAGTGGTAGGCACGACAGTTCCTCACCCTTCCGAGATGTTGGAGTTGTTTCCCAAATCCTCCATTTCCTGCACTTGTGGAGCAACAGGGGGAGGCAATCCTAGAGTCTCTGTATCAGTACTCCCGTCCTTCGATCAGTCATTTTTTTCACGGGGCCCCCTAAAGGGATACTTGGGCTCGTCCACCTCCATGTCAACCCAGCTATTCCATGCATGGGAAAAAGTCACTAATGTTCATGTGGTGAAAAGGGCTCTATCGTTAAAAGAATCTATAAACTGGTTCATCAATAGGAATTCCAATTTGGCTCAAACTCTAATTGGAAACATCATGTCTCTGACAGGCCCTGATTTCCCTCTAGAAGAGGCCCCTGTTTTCAAACGGACAGGGTCAGCCTTGCATAGGTTCAAGTCTGCCAGATACAGTGAAGGAGGGTATTCTTCTGTTTGCCCTAACCTTCTCTCTCATATCTCTGTTAGTACAGACACTATGTCTGATTTGACCCAAAACGGGAAGAACTATGATTTCATGTTTCAGCCATTGATGCTTTATGCGCAAACATGGACATCGGAACTGGTACAGAGGGATACAAGACTTAGAGACTCCACGTTTCACTGGCACCTTCGGTGCAACAGATGTGTGAGGCCCATTGATGATATAACACTGGAAACTTCTCAGATCTTCGAGTTCCCGGATGTGTCAAAAAGGATATCCAGGATGGTTTCTGGAGCTGTCCCTCAATTTCAGAAGCTTCCTGATATCCGTCTAAGACCAGGTGATTTTGAATCCCTAAGTGGTAGAGAAAAGTCTCGCCATATAGGGTCAGCTCAGGGGCTCTTATACTCAATCTTAGTAGCAATTCACGACTCAGGATACAATGATGGGACCATCTTCCCTGTCAACATATACGGCAAAGTTTCCCCCAGAGACTATTTGAGAGGGCTTGCAAGAGGGATCTTGATAGGGTCCTCGATTTGCTTCTTGACACGAATGACAAATATTAATATTAACAGACCTCTTGAATTGATTTCAGGGGTAATTTCCTATATTCTCCTGAGGCTGGATAATCATCCCTCTCTGTATATAATGCTTAGAGAACCGTCTCTTAGAGGAGAAATATTCTCTATCCCTCAGAAAATCCCCGCCGCTTACCCAACCACTATGAGAGAAGGCAACAGATCGATTTTGTGTTACCTCCAACACGTGCTACGCTATGAGCGAGAGGCAATCACGGCGTCCCCGGAGAATGACTGGCTGTGGATCTTCTCAGACTTCAGAAGTGTGAAAATGACGTACTTGACCCTCATGACCTACCAGTCTCACCTCCTACTCCAGAGGGTTGAGAGAAACTTGTCTAAGAGTATGAGAGCTACTCTGCGACAAATGAGTTCCTTAATGAGGCAAGTGCTGGGTGGGCACGGAGAAGATACCTTGGAGTCAGACGATGACATTCAACGATTACTAAAAGACTCTTTGCGAAAGACAAGGTGGGTGGATCAAGAGGTGCGCCATGCAGCTAGAACCATGAATGGAGATTACAGCCCCGACAAGAAAGTATCCCACAAGGCAGGATGTTCAGAATGGGTCTGCTCTGCTCAACAGATTGCCGTCTCCACCTCAGCCAACCCGGCTCCTGTCTCAGAGCTTGACATTAGGGCCCTCTCTAAGAGGTTTCAAAACCCCTTGATCTCGGGCCTGAGAGTGGTTCAGTGGGCAACCGGTGCTCATTATAAGCTTAAGCCTATTCTAGATGATCTAAATGTTTTCCCATCTCTCTGTCTTGTAATTGGAGACGGGTCAGGGGGAATATCAAGGGCAGTTCTCAACATGTTTCCAGATTCTAAGCTTGTGTTCAACAGCCTATTGGAGGTGAATGATCTGATGGCTTCCGGAACACATCCACTGCCTCCTTCAGCAATCATGAGTGGAGGAGATGACATCATCTCCAGAGTGATAGACTTTGACTCAATATGGGAGAAACCGTCCGACCTGAGGAACTCGGCCACCTGGAGATACTTCCAGTCGGTTCAAAAACAGGTCAACATGTCGTATGACCTCATTATTTGTGATGCAGAAGTTACTGATATTGCATCTATCAACCGGATAACTCTGTTGATGTCTGATTTCGCATTGTCTATAGATGGACCACTTTATCTGGTCTTCAAAACTTACGGGACTATGCTAGTAAACCCGGACTATAAAGCTATTCAACATCTGTCAAGAGCGTTCCCTTCGGTCACAGGGTTTGTAACCCAAGTAACTTCATCCTTTTCTTCTGAGCTATACCTCCGGTTCTCTAAACGAGGAAAGTTTTTCAGGGACGCCGAGTACTTGACCTCTTCCACCCTTCGAGAGATGAGCCTTGTGTTGTTCAATTGCAGCAGCCCCAAAAGTGAGATGCAGAGAGCTCGTTCCTTAAACTATCAAGACCTGGTAAGGGGATTTCCTGAAGAGATCATATCAAATCCTTACAACGAAATGATCATAACTCTGATTGACAATGATGTAGAGTCCTTCCTAGTCCACAAGATGGTGGATGATCTTGAGCTACAGAGGGGAACTCTGTCTAAAGTGGCTATCATTATATCCATCATGATCGTTTTTTCCAATAGAGTCTTCAACATTTCCAAACCTTTGACTGACCCCTTGTTCTACCCCCCATCTGATCCTAAAATCCTGAGGCACTTCAACATATGTTGCAGTACTATGATGTATCTATCTACCGCTTTGGGCGACGTCCCTAGCTTCGCAAGACTTCATGACCTGTATAACCGACCTATAACTTATTACTTCAGAAAACAAGTTATTCGAGGGAATATTTATCTATCTTGGAGTTGGTCCGATGATACCCCAGTGTTCAAGAGAGTAGCCTGTAATTCTAGCTTGAGTCTGTCATCTCACTGGATCAGGTTGATCTACAAGATAGTGAAGACTACCAGACTCATTGGCAGCATAAAAGACCTATCAGGAGAGGTAGAACGACATCTTCATGGGTATAACAGATGGATCACCCTCGAGGATATCCGATCTAGATCATCCCTACTAGATTACAGTTGTTTGTAA。
SEQ ID NO 2如下所示:
ATGGATGCCGACAAGATTGTGTTCAAAGTCAATAATCAGGTGGTCTCTTTGAAGCCTGAGATTATCGTGGATCAATATGAGTACAAGTACCCTGCCATCAAGGATTTGAAAAAGCCTTGTATCACCCTAGGGAAAGCCCCCGACTTGAACAAAGCATACAAATCAGTTTTATCAGGCATGAATGCCGCCAAACTTGATCCGGATGATGTATGCTCCTACTTGGCAGCAGCAATGCAGTTCTTTGAGGGGACATGTCCGGAAGACTGGACCAGCTATGGAATCCTGATTGCACGAAAAGGAGACAGGATCACCCCAAACTCTCTAGTGGAGATAAAGCGTACTGATGTAGAAGGGAATTGGGCTCTGACAGGAGGCATGGAATTGACAAGGGACCCCACTGTCTCTGAACATGCATCTTTAGTCGGTCTTCTCCTGAGTCTGTACAGGTTGAGCAAAATATCAGGACAGAACACTGGTAACTATAAGACAAACATTGCAGATAGGATAGAGCAGATTTTCGAGACAGCACCTTTTGTTAAGATCGTGGAACACCATACCCTAATGACAACTCACAAGATGTGTGCTAATTGGAGTACTATACCGAACTTCAGATTTTTGGCCGGAACCTACGACATGTTTTTCTCACGGATTGAGCATCTGTATTCGGCAATCAGAGTGGGCACAGTCGTCACCGCTTATGAAGACTGCTCAGGACTGGTATCGTTTACAGGGTTCATAAAGCAGATCAATCTCACCGCAAGGGAAGCAATACTATATTTCTTCCACAAGAACTTTGAGGAAGAGATAAGAAGAATGTTCGAGCCAGGGCAAGAGACAGCTGTTCCTCACTCTTATTTCATCCACTTCCGTTCACTAGGCTTGAGTGGGAAGTCTCCTTATTCATCGAATGCTGTCGGTCATGTGTTCAATCTCATTCACTTTGTTGGATGCTACATGGGTCAAGTCAGATCTCTAAATGCGACGGTTATTGCTGCATGTGCCCCTCATGAGATGTCTGTTCTAGGGGGCTATTTGGGAGAGGAATTCTTCGGAAAAGGGACATTTGAAAGAAGGTTCTTCAGAGACGAGAAAGAACTTCAAGAATATGAGGCGGCTGAACTAACAAAGACCGACGTGGCACTGGCAGATGACGGAACCGTCAACTCTGATGACGAGGACTATTTCTCCGGTGAAACCAGAAGTCCAGAAGCTGTCTATACTCGAATCATGATGAATGGAGGTCGACTGAAGAGATCTCATATACGGAGATATGTCTCAGTCAGTTCCAATCATCAAGCCCGTCCAAACTCATTCGCCGAATTTTTAAACAAGACGTATTCGAATGACTCATAAGGAGTTGATTGACAGGGTGCCGGAAATCTATAGATTGTATATATCCATCATGAAAAAAACTAACACTCCTCCTTTCAAACCATCCCAAATATGAGCAAGATCTTTGTTAATCCGAGTGCAATCAGAGCCGGTCTGGCCGATCTTGAGATGGCCGAAGAGACTGTTGATCTGATCAACAGAAACATAGAAGACAATCAGGCTCATCTCCAGGGAGAACCCATAGAAGTGGACAACCTCCCTGAGGACATGAAGCGACTTCACCTGGACGATGAAAAATCGTCCAACCTTGGTGAGATGGTTAGGGTGGGAGAAGGCAAGTATCGAGAGGACTTTCAGATGGATGAGGGAGAGGACCCCAACCTCCTGTTCCAATCGTACCTGGATAATGTCGGAGTCCAAATAGTCAGACAAATGAGGTCAGGAGAGAGATTCCTCAAGATATGGTCACAGACCATAGAGGAAATTGTATCCTATGTCACGGTCAACTTTCCTAACCCTCCAAGAAGGTCTTCGGAGGATAAATCAACCCAGACTACTGGCCGAGAGCTCAAGAAGGAGACAACGTCTGCTTTCTCTCAGAGAGAAAGCCAACCTTCGAAAGCTAGGATGGTGGCTCAAGTTGCCTCTGGTCCTCCAGCCCTTGAATGGTCAGCCGCCAATGAAGAAGATGATCTATCAGTAGAGGCTGAGATCGCTCATCAGATTGCTGAAAGCTTTTCCAAGAAGTACAAGTTTCCCTCCCGATCTTCAGGAATATTCTTGTATAATTTTGAGCAACTGAAGATGaACCTTGACGACATAGTTAAAGAGGCAAAAAATGTACCGGGCGTGACCCGTCTGGCCCATGATGGATCCAAAATCCCCCTGAGATGTGTACTGGGATGGGTCGCTTTGGCCAATTCCAAAAAATTCCAATTACTAGTCGAGGCTGACAAGCTAAGCAAAATCATGCAAGATGATTTGAATCGCTATACATCCTGCTAACCGAGTTTTCGAACTCAGTCCCTCCAGATAATGAAAACTGAGATGTTATGGAGTAGACATGAAAAAAACAGGCAACACCACTGATAAAATGAACGTTCTACGCAAGATAGTGAAAAAATGTAGGGATGAGGACACTCAAAAGCCCTCTCCTGTGTCAGCCCCTCCGGATGACGATGACCTGTGGCTTCCACCTCCTGAATATGTCCCGCTGAAAGAACTCACAAGCAAGAAGAACATGAGGAACTTTTGTGTCAACGGGGATGTTAAAGCGTGTAGCCCAAATGGTTACTCATTCAGGATTTTGCGGCACATTCTGAGATCATTCAACGAGATATACTCTGGGAATCATAGGATGATTGGGTTAGTCAAAGTTGTTGTTGGACTAGCTTTATCAGGAGCTCCAGTACCTGAGGGCATGAACTGGGTATACAAATTGAGGAGAACCCTTATATTCCAGTGGGCTGATTCCAGGGGCCCTCTTGAAGGGGAGGAGTTAGAATACTCTCAAGAGATCACTTGGGATGATGATACTGAATTCGTCGGATTGCAAATAAGAGTGAGCGCAAGACAATGTCATATTCAAGGCAGGATCTGGTGTATCAACACGAACTCGAGGGCATGTCAACTATGGTCTGACATGTCTCTTCAGACACAAAGGTCTGAAGAGGACAAAGACTCTTCTCTGCTTCTAGAATAATCAGATTATATCCTGCAAGTTTATCACTTGTTTACCTCTGGAGGAGAGAGCATACAGGCTTGACTCCGATCCTTGGGAGCAATAGAACAAAAAAACACACGTTATGGTGCCGTTAAATCGCTGCATTTTATCAAAGTCAAGTTGATAACCTTTACATTTTGAGCCTCTTGGATGTGAAAAAAACTATTAACATCCCTCAAAAGACTTAAGGAAAGATGGTTCCTCAGGTTCTTTTGTTTGTACCCCTTCTGGGTTTTTCGTTGTGTTTCGGGAAGTTCCCCATTTACACGATACCAGACGAACTTGGTCCCTGGAGCCCTATTGACATACACCATCTCAGCTGTCCAAATAACCTGGTTGTGGAGGATGAAGGATGTACCAACCTGTCCGAGTTCTCCTACATGGAACTCAAAGTGGGATACATCTTAGCCATCAAAGTGAACGGGTTCACTTGCACAGGTGTTGTGACAGAGGCAGAGACCTACACCAACTTTGTTGGTTATGTCACAACCACATTCAAGAGAAAGCATTTCCGCCCCACCCCAGACGCATGTAGAGCCGCGTATAACTGGAAGATGGCCGGTGACCCCAGATATGAAGAGTCCCTACACAATCCATACCCCGACTACCACTGGCTTCGAACTGTAAGAACCACCAAAGAGTCCCTCATTATCATATCCCCAAGTGTGACAGATTTGGACCCATATGACAAATCCCTTCACTCAAGGGTCTTCCCTGGCGGAAAGTGCTCAGGAATAACGGTGTCCTCTACCTACTGCTCAACTAACCATGATTACACCATTTGGATGCCCGAGAATCCGAGACCAAGCACACCTTGTGACATTTTTACCAATAGCAGAGGGAAGAGAGCATCCAAAGGGAACAAGACTTGCGGCTTTGTGGATGAAAGAGGCCTGTATAAGTCTCTAAAAGGAGCATGCAGGCTCAAGTTATGTGGAGTTCTTGGACTTAGACTTATGGATGGAACATGGGTCGCGATGCAAACATCAGATGAGACCAAATGGTGCCCTCCAGATCAGTTGGTGAATTTGCACGACTTTCGCTCAGACGAGATTGAGCATCTCGTTGTGGAGGAGTTAGTCAAGAAAAGAGAGGAATGTCTGGATGCATTAGAGTCCATCATGACCACCAAGTCAGTAAGTTTCAGACGTCTCAGTCACCTGAGaAAACTTGTCCCAGGGTTTGGAAAAGCATATACCATATTCAACAAAACCTTGATGGAGGCTGATGCTCACTACAAGTCAGTCCGGACCTGGAATGAGATCATCCCCTCAAAAGGGTGTTTGAAAGTTGGAGGAAGGTGCCATCCTCATGTGAACGGGGTGTTTTTCAATGGTATAATATTAGGGCCTGACGGCCATGTCCTAATCCCAGAGATGCAATCATCCCTCCTCCAGCAACATATGGAGTTGTTGAAATCTTCAGTTATCCCCCTGATGCACCCCCTGGCAGACCCTTCTACAGTTTTCAAAGAAGGTGATGAGGCTGAGGATTTTGTTGAAGTTCACCTCCCCGATGTGTACAAACAGATCTCAGGGGTTGACCTGGGTCTCCCGAACTGGGGAAAGTATGTATTGATGACTGCAGGGGCCATGATTGGCCTGGTGTTGATATTTTCCCTAATGACATGGTGCAGAAGAGCCAATCGACCAGAATCGAAACAACGCAGTTTTGGAGGGACAGGGAGGAATGTGTCAGTCACTTCCCAAAGCGGAAAAGTCATACCTTCATGGGAATCATATAGGAGTGGAGGTGAGATCAGACTGTGAAGGCCGGTCATCCTTTTGACGATTCCAGTCCCGAGGATAACCTCCTCTCGGGATTGGGGGGAATCTTTGGATCCAGTAGTCCTCCTTGAACTCCGTCCAACAGAGTAGATTCAAGAGTCATAAGACTTTCATTAATCATTTCAGTTGATCAGACATGGTCGTGTAGATTCTCTTAATACGGGAGATCTTCTAGCAGTTTCAGTGACCAACGGTGCTTTCATTCTCCAGGAACTGATACCAAAGGTTGTGGACAGGCCAAGGGGTACTTCGGATGACTCTGTGCTTGGGCACAGAAAGAGGTCGTAGTGTGCCCCCCGATAGCGGACTCGACATGAATCAACTAAGAAAGGCAATCTGCCTCCCATGATGGACATAAGCAATAGTTCACAACCATCTTGCATCTCAGTGAAGTGTACATAACTATTGAGGGCTGGGTCATCTAAGCATTTCAGTCGAGAAAAAAACTGTAGACCAAAAGAACAACTAGCAACACTTCTCATCCAGAGACCCATATCAAGATGCTAGATCCGGGAGAGGTTTATGATGACCCTGTTGATCCAATTGAGTCAGAGGCTGAACCCAGAGGAACCCCCACTGTCCCCAACATCTTGAGGAACTCCGACTACAATCTCAATTCTCCTTTGATAGAGGATCCTGCCAAACTAATGTTAGAATGGTTGAATACAGGGAACAGACCTTATCGGATGGCCTTGACAGACAATTGCTCCAGGTCTTACAAAGTTTTGAAAGATTATTTCAAGAAAGTAGATTTGGGTTCTCTCAAAGTGGGCGGAACTGCTGCACAGTCAATGGTTTCTCTCTGGTTGTGTGGTGCCCACTCTGAATCAAACAGGAGCCGGAGATGTATAACCGACTTGGCCCATTTCTATTCCAAGTCATCCCCCATAGAGAAGCTATTGAATTGTACGTTAGGAAACAGAGGCCTGAGAATCCCACCAGAGGGGGTGTTAAATTGCCTCGAGAGGGTCAATTATGACAAGGCATTTGGGAGGTATCTGGCCAACACGTATTCCTCTTACTTGTTTTTCCATGTAATCACCTTATACATGAATGCCTTAGACTGGGAAGAGGAAAAGACCATCCTGGCATTATGGAAAGATATAACCTCAGTGGATACCGAGAAGGACTTGGTCAAATTCAAAGATCAAATATGGGGACTGTTGATTGTGACAAAGGACTTTGTTTACTCTCAGAGTTCAAACTGTCTTTTTGACAGAAACTACACACTGATGCTAAAGGATCTTTTCTTGTCTCGATTCAACTCCTTAATGATTCTGCTTTCTCCCCCTGAGCCCCGATACTCAGATGACTTAATATCTCAGCTGTGCCAGCTATACATCGCTGGGGATCAAGTCTTGTCCATGTGTGGGAACTCCGGCTATGaAGTCATCAAAATATTGGAGCCATATGTCGTGAACAGTTTGGTCCAGAGGGCAGAGAAGTTTAGGCCTCTCATCCACCCCTTGGGAGACTTTCCTATGTtCATAAAAGACAAGGTGAATCAACTTGAAGGGACTTTTGGTCCCAGTGCAAAGAGGTTTTTTAGGGTTTTAGATCAATTCGACAACATACATGACTTAGTATTTGTGTATGGCTGTTACAGACATTGGGGGCACCCCTATATAGATTATCGGAAGGGTCTGTCGAAACTATATGATCAAGTTCACATTAAGAAAGTAATAGATAAGTCCTACCAGGAGTGTTTAGCAAGTGACTTGGCCAGAAGGATCCTCAGATGGGGATTTGACAAGTACTCCAAATGGTATCTAGATTCAAGATTCCTTGCCCGAGACCACCCCTTGACTCCTTATGTCAAGACCCAAACATGGCCACCCAAACATATAGTAGACTTGGTGGGGGACACATGGCATAAGCTCCCGATCACGCAGATCTTTGAGATTCCTGAATCAATGGACCCGTCAGAGATACTGGATGACAAATCACATTCTTTCACCAGAACAAGGTTAGCTTCTTGGCTGTCAGAGAACCGAGGGGGGCCTGTTCCTAGCGAGAAGGTCATTATCACGGCCCTGTCTAAGCCACCTGTCAATCCCCGAGAGTTTTTGAAATCTATAGACCTCGGAGGATTGCCAGATGAGGATTTGATAATTGGCCTCAAACCAAAGGAACGGGAGTTGAAGATCGAGGGCCGATTCTTTGCTCTAATGTCATGGAATCTAAGATTATATTTTGTCATCACCGAAAAGCTCTTGGCCAACTACATTTTGCCACTTTTTGACGCACTGACTATGACAGACAACCTGAACAAGGTGTTCAAAAAGTTGATCGACAGGGTCACCGGGCAAGGGCTTTTGGACTATTCTAGGGTCACATACGCATTTCACCTGGACTATGAGAAATGGAACAATCATCAAAGATTGGAGTCAACAGAGGATGTATTTTCTGTCCTAGATCAGGTGTTTGGATTGAAGAGGGTGTTTTCTAGAACACACGAGTTTTTTCAGAAGTCCTGGATCTATTATtCAGACAGATCAGACCTCATTGGGTTATGGGAGGACCAAATATATTGCTTGGATATGTCTAACGGCCCAACTTGCTGGAATGGCCAAGATGGCGGGCTAGAGGGCTTACGGCAGAAGGGCTGGAGTCTAGTCAGTTTATTAATGATAGATAGAGAATCTCAAACCAGGAACACAAGAACCAAGATACTAGCTCAAGGAGACAACCAGGTTCTGTGTCCTACATACATGTTGTCACCGGGATTGTCTCAAGAGGGGCTTCTCTATGAGTTAGAGAGCATATCAAGGAATGCACTCTCAATATACCGAGCTATCGAGGAAGGAGCATCTAAGCTGGGGTTGATCATCAAGAAGGAAGAGACCATGTGTAGTTATGACTTTCTCATATATGGGAAGACCCCCTTATTTCGAGGCAACATATTGGTGCCTGAATCCAAAAGATGGGCCCGAGTCTCTTGCATCTCTAACGACCAAATAGTCAACCTCGCCAATATAATGTCGACAGTATCCACCAATGCGCTGACAGTGGCACAACACTCTCAATCTCTGATCAAACCTATGAGGGATTTTCTGCTCATGTCAGTACAGGCAGTTTTCCACTACCTGTTGTTTAGCCCAATCCTAAAAGGCAGAGTTTATAAGATTCTGAGTGCTGAAGGGGAGAGCTTTCTCCTAGCCATGTCGCGGATAATCTACCTAGATCCTTCTTTGGGAGGGGTGTCTGGAATGTCTCTCGGGAGGTTCCATATACGTCAGTTCTCAGACCCTGTCTCTGAAGGGTTGTCATTCTGGAGAGAGATCTGGTTAGGCTCTCACGAGTCCTGGATTCACGCGTTGTGTCAAGAGGCCGGGAACCCCGATCTTGGAGAGAGAACACTCGAGAGCTTCACTCGCCTTTTAGAAGATCCTACTACCTTAAATATCAAAGGAGGGGCCAGCCCTACCATTCTACTCAAGGATGCTATCAGAAAGGCTCTGTACGACGAGGTGGACAAGGTGGAAAATTCAGAGTTTCGAGAGGCAATCCTGCTGTCCAAGACCCATAGAGATAACTTTATACTCTTTTTAAAATCTGTTGAGCCTCTGTTCCCTCGATTTCTCAGTGAGCTCTTCAGTTCGTCTTTCTTGGGAATACCGGAGTCAATCATTGGACTGATACAAAACTCCCGGACAATAAGAAGGCAGTTTAGAAAGAGTCTCTCAAGAACTTTAGAAGAGTCCTTCTACAACTCAGAGATCCACGGGATTAATCGGATAACCCAGACACCTCAAAGGGTCGGAAGGGTGTGGCCTTGCTCTTCAGAGAGGGCAGATCTACTTAGGGAGATCTCTTGGGGGAGGAAAGTGGTAGGCACGACAGTTCCTCACCCTTCCGAGATGTTGGAGTTGTTTCCCAAATCCTCCATTTCCTGCACTTGTGGAGCAACAGGGGGAGGCAATCCTAGAGTCTCTGTATCAGTACTCCCGTCCTTCGATCAGTCATTTTTTTCACGGGGCCCCCTAAAGGGATACTTGGGCTCGTCCACCTCCATGTCAACCCAGCTATTCCATGCATGGGAAAAAGTCACTAATGTTCATGTGGTGAAAAGGGCTCTATCGTTAAAAGAATCTATAAACTGGTTCATCAATAGGAATTCCAATTTGGCTCAAACTCTAATTGGAAACATCATGTCTCTGACAGGCCCTGATTTCCCTCTAGAAGAGGCCCCTGTTTTCAAACGGACAGGGTCAGCCTTGCATAGGTTCAAGTCTGCCAGATACAGTGAAGGAGGGTATTCTTCTGTTTGCCCTAACCTTCTCTCTCATATCTCTGTTAGTACAGACACTATGTCTGATTTGACCCAAAACGGGAAGAACTATGATTTCATGTTTCAGCCATTGATGCTTTATGCGCAAACATGGACATCGGAACTGGTACAGAGGGATACAAGACTTAGAGACTCCACGTTTCACTGGCACCTTCGGTGCAACAGATGTGTGAGGCCCATTGATGATATAACACTGGAAACTTCTCAGATCTTCGAGTTCCCGGATGTGTCAAAAAGGATATCCAGGATGGTTTCTGGAGCTGTCCCTCAATTTCAGAAGCTTCCTGATATCCGTCTAAGACCAGGTGATTTTGAATCCCTAAGTGGTAGAGAAAAGTCTCGCCATATAGGGTCAGCTCAGGGGCTCTTATACTCAATCTTAGTAGCAATTCACGACTCAGGATACAATGATGGGACCATCTTCCCTGTCAACATATACGGCAAAGTTTCCCCCAGAGACTATTTGAGAGGGCTTGCAAGAGGGATCTTGATAGGGTCCTCGATTTGCTTCTTGACACGAATGACAAATATTAATATTAACAGACCTCTTGAATTGATTTCAGGGGTAATTTCCTATATTCTCCTGAGGCTGGATAATCATCCCTCTCTGTATATAATGCTTAGAGAACCGTCTCTTAGAGGAGAAATATTCTCTATCCCTCAGAAAATCCCCGCCGCTTACCCAACCACTATGAGAGAAGGCAACAGATCGATTTTGTGTTACCTCCAACACGTGCTACGCTATGAGCGAGAGGCAATCACGGCGTCCCCGGAGAATGACTGGCTGTGGATCTTCTCAGACTTCAGAAGTGTGAAAATGACGTACTTGACCCTCATGACCTACCAGTCTCACCTCCTACTCCAGAGGGTTGAGAGAAACTTGTCTAAGAGTATGAGAGCTACTCTGCGACAAATGAGTTCCTTAATGAGGCAAGTGCTGGGTGGGCACGGAGAAGATACCTTGGAGTCAGACGATGACATTCAACGATTACTAAAAGACTCTTTGCGAAAGACAAGGTGGGTGGATCAAGAGGTGCGCCATGCAGCTAGAACCATGAATGGAGATTACAGCCCCGACAAGAAAGTATCCCACAAGGCAGGATGTTCAGAATGGGTCTGCTCTGCTCAACAGATTGCCGTCTCCACCTCAGCCAACCCGGCTCCTGTCTCAGAGCTTGACATTAGGGCCCTCTCTAAGAGGTTTCAAAACCCCTTGATCTCGGGCCTGAGAGTGGTTCAGTGGGCAACCGGTGCTCATTATAAGCTTAAGCCTATTCTAGATGATCTAAATGTTTTCCCATCTCTCTGTCTTGTAATTGGAGACGGGTCAGGGGGAATATCAAGGGCAGTTCTCAACATGTTTCCAGATTCTAAGCTTGTGTTCAACAGCCTATTGGAGGTGAATGATCTGATGGCTTCCGGAACACATCCACTGCCTCCTTCAGCAATCATGAGTGGAGGAGATGACATCATCTCCAGAGTGATAGACTTTGACTCAATATGGGAGAAACCGTCCGACCTGAGGAACTCGGCCACCTGGAGATACTTCCAGTCGGTTCAAAAACAGGTCAACATGTCGTATGACCTCATTATTTGTGATGCAGAAGTTACTGATATTGCATCTATCAACCGGATAACTCTGTTGATGTCTGATTTCGCATTGTCTATAGATGGACCACTTTATCTGGTCTTCAAAACTTACGGGACTATGCTAGTAAACCCGGACTATAAAGCTATTCAACATCTGTCAAGAGCGTTCCCTTCGGTCACAGGGTTTGTAACCCAAGTAACTTCATCCTTTTCTTCTGAGCTATACCTCCGGTTCTCTAAACGAGGAAAGTTTTTCAGGGACGCCGAGTACTTGACCTCTTCCACCCTTCGAGAGATGAGCCTTGTGTTGTTCAATTGCAGCAGCCCCAAAAGTGAGATGCAGAGAGCTCGTTCCTTAAACTATCAAGACCTGGTAAGGGGATTTCCTGAAGAGATCATATCAAATCCTTACAACGAAATGATCATAACTCTGATTGACAATGATGTAGAGTCCTTCCTAGTCCACAAGATGGTGGATGATCTTGAGCTACAGAGGGGAACTCTGTCTAAAGTGGCTATCATTATATCCATCATGATCGTTTTTTCCAATAGAGTCTTCAACATTTCCAAACCTTTGACTGACCCCTTGTTCTACCCCCCATCTGATCCTAAAATCCTGAGGCACTTCAACATATGTTGCAGTACTATGATGTATCTATCTACCGCTTTGGGCGACGTCCCTAGCTTCGCAAGACTTCATGACCTGTATAACCGACCTATAACTTATTACTTCAGAAAACAAGTTATTCGAGGGAATATTTATCTATCTTGGAGTTGGTCCGATGATACCCCAGTGTTCAAGAGAGTAGCCTGTAATTCTAGCTTGAGTCTGTCATCTCACTGGATCAGGTTGATCTACAAGATAGTGAAGACTACCAGACTCATTGGCAGCATAAAAGACCTATCAGGAGAGGTAGAACGACATCTTCATGGGTATAACAGATGGATCACCCTCGAGGATATCCGATCTAGATCATCCCTACTAGATTACAGTTGTTTGTAA。
附图说明
图1本发明一实施例中采用动物法检测PM株各代病毒滴度结果图谱。
图2本发明一实施例中采用直接免疫荧光法检测PM株各代病毒滴度结果图谱。
图3本发明一实施例中采用动物法检测PV株各代病毒滴度结果图谱。
图4本发明一实施例中采用直接免疫荧光法检测PV株各代病毒滴度结果图谱。
具体实施方式
下面结合具体实施例对本发明作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案,而不能以此来限制本发明的保护范围。
下面结合实施例对本发明专利进一步说明。
本发明中,试材皆为普通市售品,皆可于市场购得。
本发明提供一种基于体内外交叉的狂犬病疫苗病毒的培养方法,包括以下步骤:
S1体内筛选:将E0代狂犬病毒毒种在流水中融化、倍比稀释后,小鼠脑内接种,取发病小鼠鼠脑分离出病毒,对分离出的病毒进行滴度检测,对于滴度不低于4.0 lg CCID50/mL的病毒记为E1代病毒;
小鼠为11-13g的KM小鼠,每每只注射毒种0.03mL,每个稀释度接种4-6只小鼠;小鼠脑内接种后,若3-4天发现小鼠死亡,则进行无菌取鼠脑进行病毒的滴度检测;若接种15天仍不发病或接种后3日内死亡的小鼠均淘汰。
S2体外筛选:
将体外筛选所用的细胞复苏后,在细胞瓶中进行消化、传代,35~37℃培养箱静置培养3-7天,至长成致密单层;用于体外筛选的细胞为Vero细胞、WI-38、MRC-5、2BS或KMB-17。
将E1代病毒离心处理后取上清按照MOI 0.001-0.1接种于细胞瓶中的单层细胞,补加细胞培养液至覆盖细胞表面,35~37℃培养箱中孵育1-2h;同时,取离心处理后的E1代病毒按照MOI 0.001-0.1接种于长满单层细胞的96孔板中用于细胞病变检测;
培养瓶中继续补加培养液至培养瓶体积的5-8%,培养3-5天;检测感染病毒细胞的比例,病毒感染比例低于80%的培养瓶淘汰;对于高于80%的培养瓶,弃去培养液,按照1:1进行再次传代,35~37℃培养箱静置培养2-3天,弃去细胞培养液后,加入1.5-2倍的病毒培养液,置于33~35℃培养箱中培养3-7天,间隔时间段检测病毒感染细胞的比例,对于感染时间最短、感染比例最高的细胞取上清液,置于-70度以下保存,记为E2代病毒;
S3将E2代病毒重复步骤S1获得E3代病毒,将E3代病毒重复步骤S2获得细胞上清液为E4代病毒;
S4保存E4代病毒,并将步骤S3的细胞消化成细胞悬液,1:1传代培养2-3天,取上清病毒液;
S5病毒提取:将E4代病毒和步骤S4传代培养后的上清病毒液合并,在2-8度条件下,与预冷的PEG溶液以2:1的比例混合、过夜,离心后收集病毒沉淀,加入0.01M PBS过夜溶解,离心得到病毒粗提液;将病毒粗提液于50~100KD的超滤浓缩管中浓缩,后过0.22μm过滤膜过滤,获得浓缩毒种;
S6向浓缩毒种中加入15-30%的牛血清,分装保存、备用。
上述过程中,细胞培养液为含2~10%牛血清和0.01~0.1%谷氨酰胺的MEM培养液,pH为6.8~7.2;病毒培养液为含1~5%牛血清、0.2~2%人血白蛋白和0.01%~0.1%谷氨酰胺的MEM培养液,pH为7.5~8.0;PEG溶液的浓度为15~30%。
并以PM株和PV株两株狂犬病病毒毒株为例进行验证本发明培养方法的技术效果。
采用动物法和直接免疫荧光法对各代狂犬病毒滴度检测,结果如表1和表2、图1-图4所示。
表1 PM株各代病毒滴度检测表
表2 PV株各代病毒滴度检测表
从表1-2,图1-图4可以看出,对于PM株,采用不同的方法检测均显示,狂犬病病毒滴度,从E0代的2.5 logLD50/mL升至7.3 logLD50/mL以上;对于PV株,采用不同的方法检测均显示,狂犬病病毒滴度,从E0代的2.0 logLD50/mL升至7.5 logLD50/mL以上。
实施例2 PM株和PV株病毒滴度稳定性检测
对采用上述培养方法获得的两株病毒浓缩病毒分别在第6个月、12个月、24个月检测其滴度,结果如表3、表4所示。
表4 PM株筛选后浓缩毒种存放不同时间的滴度检测
表4 PV株筛选后浓缩毒种存放不同时间的滴度检测结果
从表3可以看出,PM株在两年内定期滴度检测,滴度均稳定在7.0 logLD50/mL以上,由此可知,采用本发明的培养方法获得的狂犬病病毒,其滴度稳定性好。从表4可以看出,PV株在两年内定期滴度检测,滴度均稳定在7.0 logLD50/mL以上,由此可知,采用本发明的培养方法获得的狂犬病病毒,其滴度稳定性好。
综上所述,采用本发明提高的狂犬病病毒培养方法:1.仅传代4次,PM株滴度上升至7.3 logLD50/mL,PV株滴度上升至7.5 logLD50/mL,滴度提高明显,且传代次数少、耗时短、大大降低了生产成本;2.通过2年的稳定性验证,两个毒株的滴度稳定性较好,能满足长期存放的需求;3.通过基因测序显示,对于PM株,传代11代后,无基因突变。
以上已以较佳实施例公布了本发明,然其并非用以限制本发明,凡采取等同替换或等效变换的方案所获得的技术方案,均落在本发明的保护范围内。
Claims (5)
1.一种基于体内外交叉的狂犬病疫苗病毒的培养方法,其特征在于:
S1体内筛选:将E0代狂犬病毒毒种在流水中融化、倍比稀释后,小鼠脑内接种,取发病小鼠鼠脑分离出病毒,对分离出的病毒进行滴度检测,符合滴度要求的记为E1代病毒;
S2体外筛选:
将体外筛选所用的细胞复苏后,在细胞瓶中进行消化、传代,35~37℃培养箱静置培养3-7天,至长成致密单层;用于体外筛选的细胞为Vero细胞、WI-38、MRC-5、2BS或KMB-17;
将E1代病毒离心处理后取上清按照MOI 0.001-0.1接种于细胞瓶中的单层细胞,补加细胞培养液至覆盖细胞表面,35~37℃培养箱中孵育1-2h;同时,取离心处理后的E1代病毒按照MOI 0.001-0.1接种于长满单层细胞的96孔板中用于细胞病变检测;
培养瓶中继续补加培养液至培养瓶体积的5-8%,培养3-5天;检测感染病毒细胞的比例,病毒感染比例低于80%的培养瓶淘汰;对于高于80%的培养瓶,弃去培养液,按照1:1进行再次传代,35~37℃培养箱静置培养2-3天,弃去细胞培养液后,加入1.5-2倍的病毒培养液,置于33~35℃培养箱中培养3-7天,间隔时间段检测病毒感染细胞的比例,对于感染时间最短、感染比例最高的细胞取上清液,置于-70度以下保存,记为E2代病毒;
S3将E2代病毒重复步骤S1获得E3代病毒,将E3代病毒重复步骤S2获得细胞上清液为E4代病毒;
S4保存E4代病毒,并将步骤S3的细胞消化成细胞悬液,1:1传代培养2-3天,取上清病毒液;
S5病毒提取:将E4代病毒和步骤S4传代培养后的上清病毒液合并,在2-8度条件下,与预冷的PEG溶液以2:1的比例混合、过夜,离心后收集病毒沉淀,加入0.01M PBS过夜溶解,离心得到病毒粗提液;将病毒粗提液于50~100KD的超滤浓缩管中浓缩,后过0.22μm过滤膜过滤,获得浓缩毒种;
S6向浓缩毒种中加入15-30%的牛血清,分装保存、备用;
狂犬病病毒毒种为PM株或PV株;细胞培养液为含2~10%牛血清和0.01~0.1%谷氨酰胺的MEM培养液,pH为6.8~7.2;病毒培养液为含1~5%牛血清、0.2~2%人血白蛋白和0.01%~0.1%谷氨酰胺的MEM培养液,pH为7.5~8.0;PEG溶液的浓度为15~30%。
2.根据权利要求1所述的基于体内外交叉的狂犬病疫苗病毒的培养方法,其特征在于:步骤S1中,小鼠为11-13g的KM小鼠,每每只注射毒种0.03mL,每个稀释度接种4-6只小鼠。
3.根据权利要求1所述的基于体内外交叉的狂犬病疫苗病毒的培养方法,其特征在于:步骤S1中,小鼠脑内接种后,若3-4天发现小鼠死亡,则进行无菌取鼠脑进行病毒的滴度检测;若接种15天仍不发病或接种后3日内死亡的小鼠均淘汰。
4.根据权利要求1所述的基于体内外交叉的狂犬病疫苗病毒的培养方法,其特征在于:E1代病毒的滴度不低于4.0 lg CCID50/mL
5.一种狂犬病疫苗的制备方法,其特征在于:将权利要求1-4任一项所述的培养方法获得的浓缩毒种,制备成狂犬病疫苗。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211083453.6A CN116218791B (zh) | 2022-09-06 | 2022-09-06 | 一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211083453.6A CN116218791B (zh) | 2022-09-06 | 2022-09-06 | 一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116218791A CN116218791A (zh) | 2023-06-06 |
CN116218791B true CN116218791B (zh) | 2024-02-09 |
Family
ID=86586010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211083453.6A Active CN116218791B (zh) | 2022-09-06 | 2022-09-06 | 一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116218791B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083654A (zh) * | 2012-08-27 | 2013-05-08 | 万里明 | Celligen310生物反应器制备人二倍体细胞狂犬病疫苗工艺 |
CN103146655A (zh) * | 2013-03-27 | 2013-06-12 | 广州银河阳光生物制品有限公司 | 高免疫原性狂犬病毒固定株的选育及其在疫苗开发中的应用 |
CN103468649A (zh) * | 2013-10-08 | 2013-12-25 | 云南沃森生物技术股份有限公司 | 人用狂犬疫苗毒种在人二倍体细胞上的快速适应方法 |
CN104560897A (zh) * | 2015-01-20 | 2015-04-29 | 中国食品药品检定研究院 | 狂犬病病毒减毒株及其选育方法和应用 |
CN106834239A (zh) * | 2017-01-20 | 2017-06-13 | 江苏中慧元通生物科技有限公司 | 一种无血清Vero细胞制备狂犬病疫苗原液的方法以及无血清狂犬病疫苗制品 |
-
2022
- 2022-09-06 CN CN202211083453.6A patent/CN116218791B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083654A (zh) * | 2012-08-27 | 2013-05-08 | 万里明 | Celligen310生物反应器制备人二倍体细胞狂犬病疫苗工艺 |
CN103146655A (zh) * | 2013-03-27 | 2013-06-12 | 广州银河阳光生物制品有限公司 | 高免疫原性狂犬病毒固定株的选育及其在疫苗开发中的应用 |
CN103468649A (zh) * | 2013-10-08 | 2013-12-25 | 云南沃森生物技术股份有限公司 | 人用狂犬疫苗毒种在人二倍体细胞上的快速适应方法 |
CN104560897A (zh) * | 2015-01-20 | 2015-04-29 | 中国食品药品检定研究院 | 狂犬病病毒减毒株及其选育方法和应用 |
CN106834239A (zh) * | 2017-01-20 | 2017-06-13 | 江苏中慧元通生物科技有限公司 | 一种无血清Vero细胞制备狂犬病疫苗原液的方法以及无血清狂犬病疫苗制品 |
Non-Patent Citations (2)
Title |
---|
狂犬病毒鼠脑复壮后的典型形态恢复及感染细胞内的形态发生学;韩小虎;邹啸环;江禹;宣华;涂长春;;微生物学报(第06期);全文 * |
韩小虎 ; 邹啸环 ; 江禹 ; 宣华 ; 涂长春 ; .狂犬病毒鼠脑复壮后的典型形态恢复及感染细胞内的形态发生学.微生物学报.2008,(第06期),全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN116218791A (zh) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109536461B (zh) | 一种o型口蹄疫病毒突变株及其制备方法和应用 | |
CN101695570B (zh) | 一种手足口病单、双价灭活疫苗及其制备方法 | |
Zhao et al. | Enterovirus71 virus‐like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in mice | |
US11931410B1 (en) | SARS-CoV-2 mRNA vaccine and preparation method and use thereof | |
Meng et al. | Potential of genotype VII Newcastle disease viruses to cause differential infections in chickens and ducks | |
JP2023511444A (ja) | 安定化されたnaを有する組換えインフルエンザウイルス | |
CN110218706A (zh) | 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用 | |
Khattar et al. | A Y526Q mutation in the Newcastle disease virus HN protein reduces its functional activities and attenuates virus replication and pathogenicity | |
CN113817753B (zh) | 表达SARS-CoV-2纤突蛋白或其变异体SΔ21的假型化VSV病毒构建和应用 | |
Zhang et al. | Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice | |
CN116218791B (zh) | 一种基于体内外交叉的狂犬病疫苗病毒的培养方法、及应用 | |
CN108929864B (zh) | 用于预防鸡传染性法氏囊病的致弱病毒及用途 | |
KR102623114B1 (ko) | 구제역 바이러스 백신 항원의 순도 증가 방법 | |
CN1306959C (zh) | 草鱼呼肠孤病毒抗原亚单位疫苗制备方法 | |
RU2701953C1 (ru) | Способ получения поливалентной вакцины от гриппа | |
Sun et al. | A single vaccination of chimeric bivalent virus-like particle vaccine confers protection against H9N2 and H3N2 avian influenza in commercial broilers and allows a strategy of differentiating infected from vaccinated animals | |
CN109602899B (zh) | 一种增强病毒抗原免疫原性的皮内注射技术及其在手足口病疫苗研究中的应用 | |
CN108055827B (zh) | 高成长肠病毒71型病毒株及其疫苗 | |
CN110268052A (zh) | 纯化病毒的方法 | |
CN113416714A (zh) | 一种表达埃博拉gp蛋白的重组病毒及其制备方法和应用 | |
CN114457042A (zh) | 小反刍兽疫病毒强毒反向遗传系统及动物感染模型 | |
CN113416713A (zh) | 一种重组腺病毒的构建及其应用 | |
Bukrinskaya et al. | Infective substructures of Sendai virus from infected Ehrlich ascites tumor cells | |
RU2706191C1 (ru) | Поливалентная вакцина против гриппа | |
RU2706544C1 (ru) | Концентрат вакцины от гриппа и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |